EZH2 expression in colorectal carcinoma: an evaluation of clinicopathological and prognostic value
Abstract Background Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2, catalyzes trimethylation of histone H3 lysine 27 and has been implicated in tumor progression. Aim Our study aims to assess the relationship between EZH2 expression and clinicopathologic d...
Saved in:
| Main Authors: | Diren Vuslat Cagatay, Mecdi Gurhan Balci, Gizem Issin, Fatih Demir |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02990-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential
by: Maria Saveria Gilardini Montani, et al.
Published: (2024-12-01) -
EZH-2 expression and prognostic significance in patients with low-grade non-Hodgkin lymphoma
by: Meryem Şener, et al.
Published: (2025-06-01) -
Multi-Faceted Role of Histone Methyltransferase Enhancer of Zeste 2 (EZH2) in Neuroinflammation and Emerging Targeting Options
by: Sotirios Moraitis, et al.
Published: (2025-06-01) -
Clinicopathological features and evaluation of microsatellite stability of colorectal carcinoma with cribriform comedo pattern
by: Tuğba Günler, et al.
Published: (2024-04-01) -
The epigenetic role of EZH2 in acute myeloid leukemia
by: Jinyong Fang, et al.
Published: (2024-12-01)